The company's flagship assay uses whole-genome sequencing to identify patients with high-risk multiple myeloma and determine which patients won't respond to therapies.

A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data presented at the annual meeting of the American Society of Clinical ...